Sandbox Reserved 1051: Difference between revisions

From Proteopedia
Jump to navigationJump to search
No edit summary
No edit summary
Line 32: Line 32:
[[Image:Ag85 ebselen.jpg |100 xp|left|thumb|'''Figure 3.''' Ag85C-ebselen: Ebselen covalently binds to Cys209 and forces the otherwise kinked alpha-9 helix to take on a relaxed conformation, thus allowing movement of the helix and a reduction in enzymatic activity.]]
[[Image:Ag85 ebselen.jpg |100 xp|left|thumb|'''Figure 3.''' Ag85C-ebselen: Ebselen covalently binds to Cys209 and forces the otherwise kinked alpha-9 helix to take on a relaxed conformation, thus allowing movement of the helix and a reduction in enzymatic activity.]]


[http://proteopedia.org/wiki/index.php/4qdu Ag85C-ebselen] is characterized by a covalent bond between [http://en.wikipedia.org/wiki/Ebselen Ebselen] and Cys209, thus forcing the otherwise kinked helix alpha-9 to take on a relaxed conformation. This allows movement of the helix and causes disruption of the hydrogen bonds within the catalytic triad, ultimately inactivating Ag85C.<ref name="Favrot"/>
[http://proteopedia.org/wiki/index.php/4qdu Ag85C-ebselen] is characterized by a covalent bond between [http://en.wikipedia.org/wiki/Ebselen ebselen] and Cys209, thus forcing the otherwise kinked helix alpha-9 to take on a relaxed conformation (Figure 3). This allows movement of the helix and causes disruption of the hydrogen bonds within the catalytic triad, ultimately inactivating Ag85C.<ref name="Favrot"/>


Some studies suggest that for the Ag85 complex, if the organism would mutate one of the Ag85 enzymes to generate resistance to a drug functioning similar to Ebselen, the mutant would probably display a low level of activity, thus inhibiting its function.  Additionally, targeting Cys209 is a pertinent and potential location for drug therapy.  Since any modification or mutation of Cys209 leads to either a dramatic decrease or complete loss of enzymatic activity, research suggests there is a low probability of developing resistance to a drug modifying the Cystine.  The structures and results of the following mutations and modifications support a strategy for inhibiting the Ag85 complex with mechanism-based inhibitors that first react with Ser124 to promote the relaxation of alpha-9 helix and expose Cys209; secondly, react with Cys209 side chain thiol to covalently modify this conserved residue.  Such a bifunctional inhibitor would offer specificity while minimizing the probability of selecting for drug resistant mutants.<ref name="Favrot"/>
These initial findings suggest that ebselen-like mutants characterized by alterations in Cys209 may serve as potential drug targets for ''M. tuberculosis''.  Because any modification or mutation of Cys209 in Ag85C leads to either a dramatic decrease or complete loss of enzymatic activity, research suggests there is a low probability of ''M. tuberculosis'' developing resistance to a drug modifying the Cys209.  The structures and results of the following mutations and modifications support a strategy for inhibiting the Ag85 complex as a whole with mechanism-based inhibitors that first react with Ser124 to promote the relaxation of alpha-9 helix and expose Cys209 and then react with Cys209 side chain thiol to covalently modify this conserved residue.  Such a bifunctional inhibitor would offer specificity while minimizing the probability of selecting for drug resistant mutants.<ref name="Favrot"/>


===Ag85C-Hg===
===Ag85C-Hg===